The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells

被引:180
作者
Bonjean, K
De Pauw-Gillet, MC
Defresne, MP
Colson, P
Houssier, C
Dassonneville, L
Bailly, C
Greimers, R
Wright, C
Quetin-Leclercq, J
Tits, M
Angenot, L
机构
[1] Univ Liege, Inst Anat L3, Lab Histol & Cytol, B-4020 Liege, Belgium
[2] Univ Liege, Inst Chim, Lab Chim Macromol & Chim Phys, B-4000 Cointe Ougree, Belgium
[3] IRCL, Lab Pharmacol Antitumorale, Ctr Oscar Lambret, F-59045 Lille, France
[4] IRCL, INSERM U124, F-59045 Lille, France
[5] CHU Liege B23, Lab Anat & Cytol Pathol, B-4000 Cointe Ougree, Belgium
[6] Univ Bradford, Sch Pharm, Bradford BD7 4ER, W Yorkshire, England
[7] Univ Liege, Inst Pharm, B-4000 Cointe Ougree, Belgium
[8] Univ Liege, Lab Pharmacognosie, B-4000 Cointe Ougree, Belgium
关键词
D O I
10.1021/bi972927q
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cryptolepine hydrochloride is an indoloquinoline alkaloid isolated from the roots of Clyptolepis sanguinolenta. It is characterized by a multiplicity of host-mediated biological activities, including antibacterial, antiviral, and antimalarial properties. To date, the molecular basis for its diverse biological effects remains largely uncertain. Several lines of evidence strongly suggest that DNA might correspond to its principal cellular target. Consequently, we studied the strength and mode of binding to DNA of cryptolepine by means of absorption, fluorescence, circular, and linear dichroism, as well as by a relaxation assay using DNA topoisomerases. The results of various optical and gel electrophoresis techniques converge to reveal that the alkaloid binds tightly to DNA and behaves as a typical intercalating agent. In DNAase I footprinting experiments it was found that the drug interacts preferentially with CC-rich sequences and discriminates against homo-oligomeric runs of A and T. This study has also led to the discovery that cryptolepine is a potent topoisomerase II inhibitor and a promising antitumor agent. It stabilizes topoisomerase II-DNA covalent complexes and stimulates the cutting of DNA at a subset of preexisting topoisomerase II cleavage sites. Taking advantage of the fluorescence of the indoloquinoline chromophore, fluorescence microscopy was used to map cellular uptake of the drug. Cryptolepine easily crosses the cell membranes and accumulates selectively into the nuclei rather than in the cytoplasm of B16 melanoma cells. Quantitative analyses of DNA in cells after Feulgen reaction and image cytometry reveal that the drug blocks the cell cycle in G(2)/M phases. It is also shown that the alkaloid is more potent at inhibiting DNA synthesis rather than RNA and protein synthesis. Altogether the results provide direct evidence that DNA is the primary target of cryptolepine and suggest that this alkaloid is a valid candidate for the development of tumor active compounds.
引用
收藏
页码:5136 / 5146
页数:11
相关论文
共 59 条
  • [11] CRYPTOLEPINE HYDROCHLORIDE EFFECT ON STAPHYLOCOCCUS-AUREUS
    BOAKYEYIADOM, K
    HEMANACKAH, SM
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (12) : 1510 - 1514
  • [12] Bonjean K., 1996, Phytotherapy Research, V10, pS159
  • [13] BINDING OF A DISTAMYCIN-ELLIPTICINE HYBRID MOLECULE TO DNA AND CHROMATIN - SPECTROSCOPIC, BIOCHEMICAL, AND MOLECULAR MODELING INVESTIGATIONS
    BOURDOUXHE, C
    COLSON, P
    HOUSSIER, C
    SUN, JS
    MONTENAYGARESTIER, T
    HELENE, C
    RIVALLE, C
    BISAGNI, E
    WARING, MJ
    HENICHART, JP
    BAILLY, C
    [J]. BIOCHEMISTRY, 1992, 31 (49) : 12385 - 12396
  • [14] CAPRANICO G, 1995, CURRENT PHARM DESIGN, V1, P1
  • [15] In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta
    Cimanga, K
    DeBruyne, T
    Pieters, L
    Vlietinck, AJ
    [J]. JOURNAL OF NATURAL PRODUCTS, 1997, 60 (07): : 688 - 691
  • [16] In vitro biological activities of alkaloids from Cryptolepis sanguinolenta
    Cimanga, K
    DeBruyne, T
    Lasure, A
    VanPoel, B
    Pieters, L
    Claeys, M
    VandenBerghe, D
    Kambu, K
    Tona, L
    Vlietinck, AJ
    [J]. PLANTA MEDICA, 1996, 62 (01) : 22 - 27
  • [17] Clinquart E., 1929, B ACAD R MED BELG, V9, P627
  • [18] Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA
    Colson, P
    Bailly, C
    Houssier, C
    [J]. BIOPHYSICAL CHEMISTRY, 1996, 58 (1-2) : 125 - 140
  • [19] COVEY JM, 1988, CANCER RES, V48, P860
  • [20] Delvaux E., 1931, J PHARM BELG, V13, P973